Safety evaluation of third-generation oncolytic HSV-1 G47-delta in patients with castration resistant prostate cancer.
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2016
At a glance
- Drugs DS 1647 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 01 Jun 2016 New trial record
- 10 May 2016 Safety results of first two cohorts presented at the 111th Annual Meeting of the American Urological Association.